Logging into your profile is required to purchase, complete, and print certificates for AAHFN CE Educational Courses.
Already a member? Log In
Not a member? Join Now
Create a non-member profile? Create Profile
SGLT2i Inhibitors: A Dynamic and Evolving Therapeutic Option
Topic:
SGLT2i Inhibitors: A Dynamic and Evolving Therapeutic Option
Objectives:
• Describe the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the physiology of cardiorenal disease.
• Discuss the clinical effects of SGLT2 inhibition on glycemia, major adverse cardiovascular events, hospitalization for heart failure, and renal endpoints in diabetes.
• Summarize the evolving landscape of evidence related to SGLT2 inhibition in patients without diabetes.
Speaker:
Mark Sanford, NP, CDE
This webinar is brought to you through a partnership with AstraZeneca.